The purchase will boost the company's portfolio of anti-inflammatory drugs.
India's pharmaceutical major Sun Pharma announced that it has acquired three brands — Disperzyme, Disperzyme-CD, and Phlogam from Aksigen Hospital Care.
Aksigen is a Mumbai-based research-driven healthcare entity with more than two decades of experience in the healthcare field.
Disperzyme and Phlogam completed a clinical study in India and are approved by the Drugs Controller General of India (DCGI) for post-operative inflammation in patients undergoing minor surgery and dental procedures. The brands were registered and launched in India by Aksigen in 2013, Sun Pharma said in a press statement.
“The addition of Disperzyme and Phlogam further strengthens our anti-inflammatory portfolio. This systemic enzyme therapy combination is being used to control edema and it speeds up the healing process. In a comparative clinical trial in India, the brands provided significantly better control and resolution of postoperative pain and inflammation,"
said Kirti Ganorkar, CEO-India business, Sun Pharma.
Last week Sun Pharmaceutical Industries launched its phenobarbital sodium injection, SEZABY for the treatment of neonatal seizures in the US.
SEZABY is the first and only product approved by the USFDA for the treatment of neonatal seizures in term and preterm infants, the company said.
Sun Pharma SEZABY was granted 'orphan drug' designation by the USFDA for the treatment of neonatal seizures.
Source: Mint
